A new perspective on metformin therapy in type 1 diabetes

Diabetologia. 2017 Sep;60(9):1594-1600. doi: 10.1007/s00125-017-4364-6. Epub 2017 Aug 2.


Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease.

Keywords: Atherosclerosis; Cardiovascular; Carotid intima-media thickness; Cholesterol; Metformin; Review; Type 1 diabetes.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis / metabolism
  • Cholesterol / metabolism
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Metformin / therapeutic use*


  • Hypoglycemic Agents
  • Metformin
  • Cholesterol